1. Home
  2. SNGX vs ICCM Comparison

SNGX vs ICCM Comparison

Compare SNGX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$0.37

Market Cap

8.2M

Sector

Health Care

ML Signal

N/A

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

N/A

Current Price

$1.65

Market Cap

8.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SNGX
ICCM
Founded
1987
2006
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
8.3M
IPO Year
2006
2013

Fundamental Metrics

Financial Performance
Metric
SNGX
ICCM
Price
$0.37
$1.65
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $22.67
AVG Volume (30 Days)
★ 200.0K
90.1K
Earning Date
11-06-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 57.03
N/A
EPS
N/A
★ N/A
Revenue
★ $119,371.00
N/A
Revenue This Year
N/A
$34.08
Revenue Next Year
N/A
$94.31
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.13
52 Week High
$1.97
$9.54

Technical Indicators

Market Signals
Indicator
SNGX
ICCM
Relative Strength Index (RSI) 40.65 24.80
Support Level $0.35 $0.22
Resistance Level $0.41 $2.50
Average True Range (ATR) 0.01 0.15
MACD -0.00 -0.01
Stochastic Oscillator 14.44 12.71

Price Performance

Historical Comparison
SNGX
ICCM

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: